{"product_id":"allo-business-model-canvas","title":"(ALLO) Allogene Therapeutics, Inc. Business Model Canvas Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogene’s Business Model Canvas: Strategy, Partnerships, and Market Edge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic logic behind Allogene Therapeutics, Inc.’s business model with a clear, concise Business Model Canvas. See how the company creates value, builds key partnerships, and navigates the high-stakes cell therapy market. Get the full version for deeper insight, smarter benchmarking, and stronger investment analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePartnerships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePfizer licensing and collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. lists Pfizer Inc. as a strategic alliance partner, and the licensing and collaboration support its external innovation model for allogeneic CAR-T programs. Pfizer’s 2025 revenue was $63.6 billion, underscoring the scale of the partner backing Allogene’s pipeline development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier collaboration agreement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eServier is a strategic alliance partner for Allogene Therapeutics, helping advance engineered T-cell therapies and sharing development work and know-how. The deal adds outside validation to Allogene’s platform, while Servier’s oncology reach supports broader clinical and regulatory execution across partnered programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCellectis S.A. licensing agreement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCellectis S.A. is a disclosed partner for Allogene Therapeutics, Inc., and its license gives Allogene access to foundational gene-editing tech for allogeneic CAR-T. The tie-up also supports development rights across Allogene's platform, which is central to its off-the-shelf cancer cell therapy strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNotch Therapeutics Inc. partnership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNotch Therapeutics Inc. sits in Allogene Therapeutics, Inc.'s strategic alliances and broadens its tech and research network. The tie-up supports next-generation allogeneic cell therapies, while no public deal value or milestone payments were disclosed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands research reach\u003c\/li\u003e\n\u003cli\u003eSupports next-gen cell therapy\u003c\/li\u003e\n\u003cli\u003eNo disclosed financial terms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpringWorks and MD Anderson collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. works with SpringWorks Therapeutics, Inc. on a clinical trial, while The University of Texas MD Anderson Cancer Center supports preclinical and clinical evaluation of the pipeline. Together, these ties help speed trial execution and sharpen translational research; Allogene reported $301.6 million in cash, cash equivalents and investments at March 31, 2024.\u003c\/p\u003e\n\u003cp\u003eThese are high-value partners for a cell therapy company running multiple studies, since site access and research depth can cut delays.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpringWorks: clinical trial collaboration\u003c\/li\u003e\n\u003cli\u003eMD Anderson: preclinical and clinical support\u003c\/li\u003e\n\u003cli\u003eBenefit: faster execution, better data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogene’s Big-Name Partners Power Its Cell Therapy Ambitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. relies on Pfizer Inc., Servier, Cellectis S.A., Notch Therapeutics Inc., SpringWorks Therapeutics, Inc., and The University of Texas MD Anderson Cancer Center to share gene-editing know-how, clinical execution, and translational research. Pfizer’s 2025 revenue was $63.6 billion, giving the partnership strong scale behind Allogene Therapeutics, Inc.’s platform.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer Inc.\u003c\/td\u003e\n\u003ctd\u003eStrategic alliance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCellectis S.A.\u003c\/td\u003e\n\u003ctd\u003eCore gene-editing license\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMD Anderson\u003c\/td\u003e\n\u003ctd\u003ePreclinical and clinical support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, real-world BMC of Allogene Therapeutics, mapping its cell therapy strategy, partners, channels, costs, and revenue model for investors and analysts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly maps Allogene Therapeutics’ business model to spot pain points and opportunities at a glance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for Allogene Therapeutics, Inc. that boosts credibility and helps investors verify key assumptions fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eActivities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogeneic CAR-T discovery and engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. focuses on allogeneic CAR-T discovery and engineering, building genetically engineered T-cell therapies that can be made for many patients from one donor source. Its platform is built around multiple CAR-T candidates for different cancer targets, making this the company’s core scientific activity and main R\u0026amp;D engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development across Phase I and Phase I\/II\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics runs Phase I and Phase I\/II clinical development across hematologic cancers, with key programs including UCART19, ALLO-501, ALLO-501A, and ALLO-715. This work is the core proof point for its allogeneic CAR T platform: it tests safety, dose, and early efficacy, and turns pipeline data into validation and value creation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and process development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. treats manufacturing and process development as a core activity, building its allogeneic T-cell therapies in-house and tightening process control so batches can scale reliably. UCART19 has been developed and manufactured for market release, showing how the company links process work directly to clinical and commercial readiness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory and market preparation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. has 0 marketed products, so regulatory readiness depends on clean clinical data, trial design, and CMC (chemistry, manufacturing, and controls) work for each program. In FY2024, the company reported no product revenue, which makes advancement into later-stage trials the key step before any launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuild data for regulatory filing\u003c\/li\u003e\n\u003cli\u003ePlan trials for later-stage review\u003c\/li\u003e\n\u003cli\u003eKeep launch readiness tied to compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline expansion into new targets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. is expanding its pipeline across CD70, AML, and DLL3, plus renal cell cancer, small cell lung cancer, and aggressive neuroendocrine tumors. This target expansion is a core activity because it broadens the addressable market and gives the Company more shots at clinical readouts across several high-unmet-need cancers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets multiple tumor types\u003c\/li\u003e\n\u003cli\u003eSpreads risk across programs\u003c\/li\u003e\n\u003cli\u003eBuilds a wider clinical pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogene’s Value Hinges on 4 Pipeline Programs and Clinical Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. is centered on allogeneic CAR-T R\u0026amp;D, with 4 main clinical programs and 0 marketed products, so its key work is target selection, cell-engineering, and proof-of-concept data generation. In FY2024, the Company reported no product revenue, making trial execution and CMC control the main value drivers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey activity\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical pipeline\u003c\/td\u003e\n\u003ctd\u003e4 core programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial stage\u003c\/td\u003e\n\u003ctd\u003e0 marketed products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eFY2024: $0 product revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThis Allogene Therapeutics, Inc. Business Model Canvas preview is a direct view of the exact document you’ll receive after purchase. It is not a sample or mockup—what you see here is the same professionally formatted file, with the same content and structure. Once purchased, you’ll get full access to this identical document, ready to review, edit, or present.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eResources\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogeneic T-cell therapy platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc.’s core resource is its genetically engineered allogeneic CAR-T platform, which has produced 3 named clinical programs: ALLO-501A, ALLO-316, and ALLO-715. This base technology supports repeated pipeline generation across oncology targets and is the main asset behind the company’s go-to-market model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical pipeline assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. relies on 8 core clinical assets: UCART19, ALLO-501, ALLO-501A, ALLO-715, ALLO-605, ALLO-647, ALLO-819, and the DLL3 and CD70 programs. This breadth is the key resource, since it spreads development risk across multiple allogeneic CAR-T and antibody-linked programs and supports a 2025 pipeline built around several oncology targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensed intellectual property rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. leans on licensed intellectual property rights from licensing and collaboration deals to access core cell therapy technology, know-how, and development rights. That matters because cell therapy is patent-heavy and IP control can decide who can move candidates forward and who gets blocked.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical data and trial network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc.’s clinical data and trial network are core resources because ongoing studies feed safety, efficacy, and manufacturing readouts into go\/no-go calls. Trial sites and academic partners expand patient access and evidence generation, and the company’s latest filings show it is still advancing multiple clinical programs, so each dataset directly shapes development priority and capital use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDrives safety and efficacy decisions\u003c\/li\u003e\n\u003cli\u003eCaptures manufacturing process data\u003c\/li\u003e\n\u003cli\u003eRelies on trial sites and academics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSouth San Francisco headquarters and team\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. is based in South San Francisco, California, a core Bay Area biotech hub that gives it direct access to talent, CDMO and lab networks, and clinical trial partners. Its scientific and clinical team is a key resource because cell therapy work depends on deep process, regulatory, and translational expertise.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSouth San Francisco biotech cluster access\u003c\/li\u003e\n\u003cli\u003eScientific and clinical team drives R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eLocal infrastructure supports development speed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogene’s 8-Asset Pipeline Powers Its CAR-T Edge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc.’s key resources are its 8 clinical assets, led by 3 named programs: ALLO-501A, ALLO-316, and ALLO-715. Its main edge is the allogeneic CAR-T platform plus licensed IP, which together support repeat pipeline generation and control over core cell-therapy rights.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey resource\u003c\/th\u003e\n\u003cth\u003eCount\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical assets\u003c\/td\u003e\n\u003ctd\u003e8\u003c\/td\u003e\n\u003ctd\u003ePipeline depth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNamed programs\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003ctd\u003eLead value drivers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensed IP\u003c\/td\u003e\n\u003ctd\u003eCore rights\u003c\/td\u003e\n\u003ctd\u003ePlatform access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eValue Propositions\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOff-the-shelf allogeneic CAR-T therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. builds off-the-shelf allogeneic CAR-T therapies from donor T cells, unlike autologous products made for each patient. That can cut vein-to-vein time from weeks to days, which matters in aggressive blood cancers where delays can cost treatment windows and limit access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiple hematologic cancer indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. targets multiple hematologic cancers, including CD19-positive ALL, non-Hodgkin lymphoma, large B-cell lymphoma, transformed follicular lymphoma, and multiple myeloma. That broad reach covers several high-need blood cancer segments and spreads clinical and commercial upside across distinct oncology markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into solid tumor targets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. is widening its allogeneic CAR T platform beyond blood cancers with CD70 for renal cell cancer and DLL3 for small cell lung cancer and neuroendocrine tumors. That matters because renal cell cancer is about 90% of kidney cancers, while small cell lung cancer is roughly 13% of lung cancers, so the target set opens a much larger long-term market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePotential scalable manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. builds allogeneic therapies for centralized production, so one manufacturing run can serve many patients and reduce the batch-by-batch variability seen in personalized cell therapy. That scale matters commercially: the cell therapy market was still led by highly customized autologous products in 2025, so a successful off-the-shelf platform could cut supply bottlenecks and improve unit economics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCentralized output can support steadier supply.\u003c\/li\u003e\n\u003cli\u003eLess patient-specific handling can lower complexity.\u003c\/li\u003e\n\u003cli\u003eScale can improve margins if programs work.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGenetically engineered precision oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. frames value around genetically engineered precision oncology: its allogeneic CAR-T programs aim at 3 defined cancer antigens CD19, CD52, and DLL3, so treatment is concentrated on malignant cells and not broad tissue. That antigen focus is the core of its immuno-oncology differentiation, with CD19 tied to B-cell cancers and DLL3 to small cell lung cancer.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 named antigen targets\u003c\/li\u003e\n\u003cli\u003eCD19, CD52, DLL3\u003c\/li\u003e\n\u003cli\u003eDesigned for malignant-cell selectivity\u003c\/li\u003e\n\u003cli\u003eKey immuno-oncology differentiator\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogene’s Off-the-Shelf CAR-T: Faster Supply, Broader Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. offers off-the-shelf allogeneic CAR-T therapies that aim to shorten treatment time, lower manufacturing complexity, and improve access versus patient-specific cell therapy. Its value rests on centralized production, which can support steadier supply and better scale if programs work.\u003c\/p\u003e\n\u003cp\u003eThe pipeline targets CD19, CD52, and DLL3 across blood cancers and solid tumors, including CD19-positive ALL, non-Hodgkin lymphoma, large B-cell lymphoma, multiple myeloma, renal cell cancer, and small cell lung cancer.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFocus\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eModel\u003c\/td\u003e\n\u003ctd\u003eAllogeneic CAR-T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey targets\u003c\/td\u003e\n\u003ctd\u003eCD19, CD52, DLL3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore gain\u003c\/td\u003e\n\u003ctd\u003eFaster, scalable supply\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Relationships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial participant support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. still relies on trial-based relationships: patients receive its therapies only through clinical studies at participating centers, with no routine commercial access. In 2025, that means each enrollment depends on site-level screening, consent, dosing, and repeated safety checks.\u003c\/p\u003e\n\u003cp\u003eBecause CAR-T follow-up is intensive, trial staff must coordinate visits, labs, and adverse-event monitoring across every participant, so patient support is a core operating need, not a side service.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestigator and site collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics works closely with oncologists, trial sites, and research teams to recruit patients, manage dosing, and complete follow-up. In cell therapy, site execution is a make-or-break factor; every enrolled patient depends on tight coordination across a small network of specialized centers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic medical center engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. uses academic medical center ties, including MD Anderson as a named research and clinical collaborator, to tap translational expertise and access complex cancer populations. These partnerships lift scientific credibility and help the Company sharpen cell therapy development where high-acuity, treatment-resistant patients are common.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-managed alliance relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. runs alliance management as a core operating relationship, coordinating five named partners: Pfizer, Servier, Cellectis, Notch, and SpringWorks. These ties require governance, data sharing, and joint program oversight across licensing and collaboration work.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5 key partner alliances\u003c\/li\u003e\n\u003cli\u003eOngoing governance and data sharing\u003c\/li\u003e\n\u003cli\u003eCore operating relationship\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncology community education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. uses oncology community education to keep specialists informed on trial progress and product potential, which matters in a 2025 setting where each clinical update can shape future adoption. This outreach builds awareness among oncologists and transplant centers and supports uptake if the company’s cell therapies win approval.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEducates oncologists on clinical updates\u003c\/li\u003e\n\u003cli\u003eBuilds trust with transplant centers\u003c\/li\u003e\n\u003cli\u003eSupports future approved-product adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-Only Access, Backed by 5 Key Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. builds customer relationships mainly through trial sites, oncologists, and research partners, since its CAR-T therapies are still accessed only in clinical studies in 2025. The Company also depends on five named alliances with Pfizer, Servier, Cellectis, Notch, and SpringWorks to coordinate development, data sharing, and site execution.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRelationship\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trial sites\u003c\/td\u003e\n\u003ctd\u003eOnly patient access route\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNamed alliances\u003c\/td\u003e\n\u003ctd\u003e5 key partners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology outreach\u003c\/td\u003e\n\u003ctd\u003eSupports future adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eChannels\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. uses active clinical trial sites as the main path to reach patients in development, with each site also generating the safety and efficacy data needed for regulators and payers. In 2025, the company’s cell therapy pipeline stayed centered on site-based enrollment and follow-up, so site quality and activation speed directly shape trial output.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic cancer centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAcademic cancer centers are Allogene Therapeutics, Inc.'s main research and access channel, because university partners support preclinical work and early clinical testing. MD Anderson Cancer Center is a key node in this network, helping validate CAR T assets and connect the company to high-volume specialist sites that enroll hard-to-treat blood cancer patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology investigator networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncology investigator networks give Allogene Therapeutics access to specialist physicians who spot eligible patients, run studies, and keep protocols on track. That matters in rare cancers, which make up roughly 25% of U.S. cancer cases, where enrollment is slow and site expertise drives trial speed.\u003c\/p\u003e\n\u003cp\u003eFor cell therapy programs, these networks also improve screening quality and follow-up, which can cut costly delays and help move hard-to-treat studies to readout faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStrategic collaboration agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrategic collaboration agreements let Allogene Therapeutics, Inc. move technology, data, and development work across partners, widening reach beyond its own team. This channel also supports future commercialization: its 2025 10-K still showed a cash position of about $373 million, giving it room to keep these alliances active while advancing pipeline work.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpand reach through partners\u003c\/li\u003e\n\u003cli\u003eShare data and development work\u003c\/li\u003e\n\u003cli\u003eSupport future commercialization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFuture hospital and specialty distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIf Allogene Therapeutics, Inc. wins approval, its CAR-T products would likely flow through oncology hospitals and specialty treatment centers, where infusion and follow-up can be handled in controlled settings. Patients are often monitored for 7-14 days after infusion because toxicity can escalate fast, so this channel fits the complex delivery and safety needs of cell therapy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOncology hospitals are the core access point.\u003c\/li\u003e\n\u003cli\u003eSpecialty centers support infusion and monitoring.\u003c\/li\u003e\n\u003cli\u003eControlled settings reduce safety risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis channel also supports certified staff, emergency care, and cold-chain handling tied to CAR-T logistics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogene’s Trial Network and $373M Cash Fuel CAR-T Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. reaches patients mainly through oncology trial sites, academic cancer centers, and investigator networks that can screen, enroll, and monitor CAR-T patients in controlled settings. In 2025, the company held about $373 million in cash, helping fund these site-based trials and partner channels.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trial sites\u003c\/td\u003e\n\u003ctd\u003eEnroll and follow patients\u003c\/td\u003e\n\u003ctd\u003eCore path\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic cancer centers\u003c\/td\u003e\n\u003ctd\u003eEarly testing and access\u003c\/td\u003e\n\u003ctd\u003eKey node\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash runway\u003c\/td\u003e\n\u003ctd\u003eSupports partners\u003c\/td\u003e\n\u003ctd\u003eAbout $373M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Segments\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\/R CD19-positive B-ALL patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUCART19 is aimed at relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia, a rare but high-need market in both children and adults. B-ALL is the most common pediatric cancer, and ALL causes about 6,000 U.S. cases a year, making this a core near-term patient segment for Allogene Therapeutics, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\/R lymphoma patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. targets relapsed\/refractory lymphoma patients with ALLO-501 and ALLO-501A, focused on non-Hodgkin lymphoma, large B-cell lymphoma, and transformed follicular lymphoma. This is a high-need hematologic oncology segment, with U.S. NHL cases still above 80,000 a year, so the company is building a tight lymphoma niche.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiple myeloma patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMultiple myeloma is a key customer segment for Allogene Therapeutics, Inc., with ALLO-715 and ALLO-605 aimed at a market that sees about 36,000 new U.S. cases a year and roughly 35,000 U.S. deaths. Allogene is targeting this major CAR-T opportunity with a differentiated allogeneic, off-the-shelf approach that could improve access and speed versus patient-specific therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAML, RCC, and SCLC patient groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. targets hard-to-treat oncology groups with ALLO-819 for acute myeloid leukemia, CD70 programs for renal cell cancer, and DLL3 programs for small cell lung cancer and neuroendocrine tumors. These markets are clinically urgent: AML is about 1% of cancers, RCC is about 2% to 3% of adult cancers, and SCLC is about 15% of lung cancers, so the pipeline can widen the eventual patient base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAML: high unmet need\u003c\/li\u003e\n\u003cli\u003eRCC: CD70-driven niche\u003c\/li\u003e\n\u003cli\u003eSCLC and NETs: DLL3 target\u003c\/li\u003e\n\u003cli\u003eBroadens future addressable patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncology centers and biotech partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. sells first to hospitals, transplant centers, and academic cancer centers; the U.S. has 73 NCI-designated cancer centers, which shows why these sites are key for trial use and eventual uptake. Licensing and collaboration partners also matter because they help fund development and widen reach into future commercialization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHospitals and transplant centers drive first use.\u003c\/li\u003e\n\u003cli\u003eAcademic cancer centers support trials.\u003c\/li\u003e\n\u003cli\u003ePartners help fund and scale commercialization.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogene Targets High-Need Blood Cancers and Beyond\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. serves patients with relapsed or refractory blood cancers, led by CD19-positive B-ALL, non-Hodgkin lymphoma, and multiple myeloma, where unmet need stays high and treatment centers are concentrated in major oncology hubs. Its pipeline also points to AML, RCC, SCLC, and neuroendocrine tumors, widening the addressable pool.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey need\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eB-ALL\u003c\/td\u003e\n\u003ctd\u003eRare, urgent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLymphoma\u003c\/td\u003e\n\u003ctd\u003eLarge relapsed pool\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyeloma\u003c\/td\u003e\n\u003ctd\u003eFast-growing CAR-T use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCost Structure\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and discovery spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. is still clinical-stage, so R\u0026amp;D and discovery remain the main cost burden. In FY2025, the company kept spending on new CAR-T constructs, target work, and cell-engineering research, because early-stage pipeline growth depends on steady scientific investment, not near-term sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial execution costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical trial execution costs are a major drag for Allogene Therapeutics, Inc., because Phase I and Phase I\/II studies need patient enrollment, site management, monitoring, and data analysis. With multiple active programs, clinical development stays the largest cost line, and in 2025 it continued to dominate R\u0026amp;D spending.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and process development costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. bears heavy manufacturing and process development costs because it builds engineered T-cell therapies that need scale-up, tight quality control, and reliable supply prep. For allogeneic products, manufacturing readiness is a core cost driver, since one donor-derived batch must support many patients and each lot needs strict release testing before use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeneral and administrative expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. carries recurring general and administrative costs for corporate, legal, finance, HR, and compliance work. Its South San Francisco headquarters adds fixed overhead, so this line stays high even when pipeline spending shifts; in FY2025, these functions still supported the full cell-therapy portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCorporate and legal support\u003c\/li\u003e\n\u003cli\u003eFinance, HR, and compliance\u003c\/li\u003e\n\u003cli\u003eHQ fixed overhead in South San Francisco\u003c\/li\u003e\n\u003cli\u003eSupports all pipeline programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicensing, collaboration, and regulatory costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. spent $138.6 million on R\u0026amp;D in 2025, and partner-backed programs add more fixed costs through alliance governance, legal work, and milestone tracking. Regulatory prep also burns cash fast, as FDA\/EMA-facing CMC and trial packages must be built before each program can move forward.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003e2025 R\u0026amp;D expense: $138.6 million\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eAlliance oversight and legal fees recur\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eRegulatory filing prep adds heavy spend\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogene’s FY2025 spend was led by $138.6M R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. cost structure in FY2025 was dominated by research and development, with $138.6 million spent on R\u0026amp;D as clinical-stage work, trial ops, and process development stayed the main cash burn. General and administrative costs also remained fixed overhead, while regulatory and alliance support added recurring spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost driver\u003c\/th\u003e\n\u003cth\u003eFY2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D expense\u003c\/td\u003e\n\u003ctd\u003e$138.6 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain spend areas\u003c\/td\u003e\n\u003ctd\u003eTrials, CMC, manufacturing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFixed overhead\u003c\/td\u003e\n\u003ctd\u003eHQ, legal, finance, HR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRevenue Streams\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaboration and licensing fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. uses its alliance model to earn collaboration and licensing fees while its cell-therapy programs are still in development. Partners including Pfizer, Servier, Cellectis, Notch, and SpringWorks can contribute milestone, sublicense, and research payments; this matters because Allogene still had no commercial product revenue in its latest filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestone payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMilestone payments are a progress-linked revenue stream for Allogene Therapeutics, Inc. in biotech deals, where cash can be triggered at IND filing, first patient dosing, and Phase 1\/2 advancement. In pharma partnering, each step can pay from low single-digit millions to tens of millions, so revenue rises only when technical risk falls.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUpfront partner payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUpfront partner payments are a key revenue stream for Allogene Therapeutics, Inc., with licensing deals often bringing immediate cash that can help fund early-stage development. In biotech, these fees also signal platform value and can be large; for example, major CAR-T licensing deals have included upfront checks in the tens of millions of dollars.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFuture product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. has no product sales yet, so future revenue still depends on one or more CAR-T candidates winning approval. If UCART19 or another pipeline therapy clears regulators, sales could start as a direct product stream; as of the latest public 2025 reporting, this remains pre-commercial.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0 commercial product revenue today\u003c\/li\u003e\n\u003cli\u003eSales start only after approval\u003c\/li\u003e\n\u003cli\u003eUCART19 is a key future asset\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat makes this a high-upside but still unrealized revenue stream, not the current operating base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePotential royalties on partnered programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. can earn royalties if a partner turns a licensed program into a commercial product, which is a common biotech path that adds upside without building a full sales force. In FY2025, Allogene did not disclose royalty income, so this revenue stream remains optionality, not current cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner sales can trigger royalties\u003c\/li\u003e\n\u003cli\u003eLow capex, no commercial launch needed\u003c\/li\u003e\n\u003cli\u003eFY2025 royalty income: none disclosed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogene’s Revenue Still Depends on Partner Deals, Not Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAllogene Therapeutics, Inc. revenue is still alliance-led: upfront fees, milestones, and possible royalties from partners like Pfizer, Servier, Cellectis, Notch, and SpringWorks. In FY2025, it still reported no product revenue and no disclosed royalty income, so cash flow depends on deal events, not sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eFY2025 status\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003eNone disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront\/milestones\u003c\/td\u003e\n\u003ctd\u003ePartner-driven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234012799241,"sku":"allo-business-model-canvas","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/allo-business-model.webp?v=1785710303","url":"https:\/\/dcfanalyst.com\/products\/allo-business-model-canvas","provider":"DCF Analyst","version":"1.0","type":"link"}